[Veterinary and clinical experience of the use of a beta2-receptor-stimulating sympathicomimetic agent (NAB 365) in horses with respiratory discase (author’s transl)].

This research involves a test on the effectiveness of a beta2-receptor-stimulating sympathicomimetic agent known as NAB 365 on horses with respiratory diseases, where the drug exhibited significant bronchodilative and secretolytic effects with fewer side-effects.

Study Intervention and Setting

• The research centered on the use of a beta2-receptor-stimulating sympathicomimetic agent, NAB 365, which is proposed by the manufacturer to possess a bronchial antispasmodic effect and a bronchia secretolytic property. These are deemed beneficial for treatment of respiratory conditions.
• The drug was expected to present few negative side effects on other body organs, such as the heart and intestine.
• The study was carried out at the Department of Veterinary Internal Medicine in Utrecht.

Study Participants and Administration of NAB 365

• The participants in the study were horses diagnosed with either chronic or acute respiratory diseases.
• These horses were administered with NAB 365 at a dosage of 0.8 gamma per kilogram of their body weight.

Indications of the Effectiveness of NAB 365

• NAB 365 demonstrated a significant bronchodilative effect in horses, which involves the widening of the bronchial tubes to facilitate better airflow.
• There was also an indication of a bronchial secretolytic effect. This effect involves the promotion of secretion in the bronchial tubes to help eliminate mucus and other substances.
• The drug showed a beneficial effect on the respiration of the horses. The improvement in respiration is indicative of the overall effectiveness of NAB 365.

Side Effects and Durability of NAB 365’s Therapeutic Effect

• When given at a dosage of 0.8 gamma per kilogram of body weight, twice daily, NAB 365 showed few side effects, even after continuous administration for two weeks.
• The clinical impact on respiration, a critical measure of the drug’s effectiveness, lasted almost throughout the entire day. This finding underscores the durability of the therapeutic effect of NAB 365.